
|Videos|June 18, 2015
Hepatitis C: Short Term Drug Costs Versus Long Term Care Costs
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program
2
Immuneering Panel & CEO Insights: Atebimetinib Raises the Bar for Survival and Quality of Life in Pancreatic Cancer
3
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review
4
January 2026 Product Updates
5



















